Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms - Long-term follow-up of a placebo-controlled, double-blind, multicenter trial

International Urology and Nephrology

Volumn 39, Issue 4, 2007, Pages 1137-1146

  Lopatkin, Nikolai ^a   Sivkov, Andrey ^a   Schläfke, Sandra ^b   Funk, Petra ^b   Medvedev, Alexander ^a   Engelmann, Udo ^c  

^a Institute of Urology   (Russian Federation)

^b DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

BPH; Clinical trial; Efficacy; I PSS; Long term follow up; LUTS; Sabal extract; Safety; Urtica extract

Indexed keywords

PLACEBO; SABAL EXTRACT; SABAL EXTRACT PLUS URTICA EXTRACT; UNCLASSIFIED DRUG; URTICA EXTRACT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ENDOCARDIAL DISEASE; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; INTESTINE INFECTION; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOCARDIAL DISEASE; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERICARDIAL DISEASE; PHASE 3 CLINICAL TRIAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; RESPIRATORY TRACT DISEASE; URINE FLOW RATE; UROFLOWMETRY; VALVULAR HEART DISEASE;

AGED; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SERENOA; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS; URTICA DIOICA;

EID: 36649023499     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-006-9173-7     Document Type: Article

References (28)

1. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W et al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the Triumph project. Eur Urol 42:323-328
2. Gades NM, Jacobson DJ, Girman CJ, Roberts RO, Lieber MM, Jacobsen SJ (2005) Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 95:549-553
3. Clifford GM, Farmer RD (2000) Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol 38:2-19
4. Lowe FC, Fagelman E (2002) Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 12:15-18
5. Boyle P, Robertson C, Lowe F, Roehrborn C (2004) Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93:751-756
6. Gerber GS, Fitzpatrick JM (2004) The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int 94:338-344
7. Gong EM, Gerber GS (2004) Saw palmetto and benign prostatic hyperplasia. Am J Chin Med 32:331-338
8. Wilt T, Ishani A, Mac Donald R (2002) Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev CD001423
9. Dathe G, Schmid H (1987) Phytotherapie der benignen Prostatahyperplasie (BPH). Doppelblindstudie mit Extractum Radicis urticae (ERU). Urologe B 27:223-226
10. Vontobel HP, Herzog R, Rutishauser G, Kres H (1985) Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie. Urologe A 24:49-51
11. Schneider T, Rübben H (2004) Brennnesseltrockenextrakt (Bazoton-uno) in der Langzeittherapie des benignen Prostatasyndroms (BPS). Ergebnisse einer randomisierten, doppelblinden, placebokontrollierten Multicenterstudie über 12 Monate. Urologe A 43:302-306
12. Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A, Sharma CP (2001) Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int 25:1117-1124
13. Koch E (2001) Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): Viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 67:489-500
14. Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE (2001) Tissue effects of saw palmetto and finasteride: Use of biopsy cores for in situ quantification of prostatic androgens. Urology 57:999-1005
15. Hirano T, Homma M, Oka K (1994) Effects of stinging nettle root extracts and their steroidal components on the Na+,K(+)-ATPase of the benign prostatic hyperplasia. Planta Med 60:30-33
16. Lichius JJ, Lenz C, Lindemann P, Müller HH, Aumüller G, Konrad L (1999) Antiproliferative effect of a polysaccharide fraction of a 20% methanolic extract of stinging nettle roots upon epithelial cells of the human prostate (LNCaP). Pharmazie 54:768-771
17. Mitropoulos D, Kyroudi A, Zervas A, Papadoukakis S, Giannopoulos A, Kittas C et al (2002) In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate. World J Urol 19:457-461
18. Talpur N, Echard B, Bagchi D, Bagchi M, Preuss HG (2003) Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats. Mol Cell Biochem 250:21-26
19. Wadsworth TL, Carroll JM, Mallinson RA, Roberts CT Jr, Roselli CE (2004) Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. Endocrinology 145:3205-3214
20. Metzker H, Kieser M, Hölscher U (1996) Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36:292-300
21. Sökeland J, Albrecht J (1997) Kombination aus Sabal- und Urticaextrakt vs Finasterid bei BPH. (Stad. I bis II nach Alken) - Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe A 36:327-333
22. Sökeland J (2000) Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: Analysis of prostate volume and therapeutic outcome. BJU Int 86:439-442
23. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549-1557; discussion 1564
24. Engelmann U, Bondarenko B, Walther C, Funk P, Schläfke S (2006) Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. Arzneimittelforschung 56:222-229
25. Lopatkin N, Sivkov A, Walther C, Schläfke S, Medvedev A, Avdeichuk J et al (2005) Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms - a placebo-controlled, double-blind, multicenter trial. World J Urol 23:139-146
26. Roehrborn CG, Abbou CC, Akaza H, Allona-Almagro A, Boccon-Gibod L, Ekman PE et al (2001) Clinical research criteria for studies of: Lower urinary tract symptoms (LUTS), enlarged prostate gland (EPG), bladder outlet obstruction (BOO) and benign prostatic hyperplasia (BPH). In: Chatelain C, Denis L, Foo KT, Khoury S, Mc Connell J (eds) Benign prostatic hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, 25-28 June 2000. Health Publication Ltd, Plymouth, pp 317-395
27. Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP (2002) Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 19: 297-306
28. Marberger MJ (1998) Long-term effects of finasteride in patients with benign prostatic hyperplasia: A double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 51:677-686